Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma
- 1 January 1998
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 85 (1) , 63-67
- https://doi.org/10.1046/j.1365-2168.1998.00564.x
Abstract
Background: The possible immunosuppressive effect of blood transfusion and its influence on survival after surgery for cancer makes it worthwhile to seek methods to avoid transfusion wherever possible. Patients with right-sided colonic cancer are frequently anaemic. Such patients were entered into a study that employed erythropoietin to avoid homologous transfusion. Methods: In a prospectively randomized double-blind placebo-controlled multicentre trial, patients with moderate anaemia (haemoglobin concentration greater than 8·5 g/dl and less than or equal to 13·5 g/dl) presenting with right-sided colonic cancer and scheduled for hemicolectomy were treated with recombinant human erythropoietin (epoetin β) 20000 units/day subcutaneously or placebo for at least 10 days over the operative period. Results: Perioperative treatment with epoetin β was well tolerated and there were no significant differences in morbidity and mortality. Following hemicolectomy, median cumulative blood loss in the two groups was similar (epoetin β 440 ml versus placebo 345 ml). Sixteen (33 per cent) of 48 patients treated with epoetin β and 15 (28 per cent) of 54 in the placebo group received perioperative blood transfusions (P not significant). The increase in reticulocyte count between baseline and the last preoperative value was more pronounced in the epoetin β group than in those receiving placebo (P = 0·036). Conclusion: Despite the perioperative administration of 20000 units erythropoietin per day for at least 10 days, it was not possible to reduce the intraoperative and postoperative transfusion need. None the less, a positive change in the haematological variables of treated patients was clearly discernible. The negative result may be due to the short treatment interval and to iron deficiency, which was present in the majority of patients. The general change of attitude towards allogeneic blood transfusion is demonstrated by the overall low frequency of blood transfusion in this study.Keywords
This publication has 22 references indexed in Scilit:
- Effectiveness of perioperative recombinant human erythropoietin in elective hip replacementThe Lancet, 1993
- Blood transfusion and prognosis in Dukes' B and C colorectal cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Increased Preoperative Collection of Autologous Blood with Recombinant Human Erythropoietin TherapyNew England Journal of Medicine, 1989
- Der Einflu der Transfusion von Blut and Haemoderivaten auf die Prognose des colorectalen CarcinomsLangenbecks Archives Of Surgery, 1989
- Effect of perioperative blood transfusion on recurrence of colorectal cancerBritish Journal of Surgery, 1986
- Perioperative Allogeneic Blood TransfusionsArchives of Surgery, 1985
- Relation between recurrence of cancer of the colon and blood transfusion.BMJ, 1985
- Adverse relationship between blood transfusions and survival after colectomy for colon cancerCancer, 1985
- EFFECT OF BLOOD TRANSFUSIONS ON COLONIC MALIGNANCY RECURRENCE RATEThe Lancet, 1982
- Tumor Cells Carried Through AutotransfusionJAMA, 1975